glp-1 medicaid McKee's proposed FY2027 budget drops drugs for weight loss from • Rhode Island Current Medicaid cuts have put Ozempic

Hara, R., Suzuki, R

275 Further, a novel Wnt inhibitor, SM04690 were proved to effectively relieve the pain of severe symptomatic knee osteoarthritis (OA) and appeared safe and well tolerated through phase I/II clinical trial

14 Two therapeutic strategies currently exist to overcome the short half-life of incretin hormones and pharmacologically augment the incretin effect: 1) inject GLP-1 receptor agonists that are resistant to degradation by the DPP-4 enzyme and 2) orally administer DPP-4 inhibitors that delay the enzymatic degradation of naturally secreted incretin hormones ( Figure 2 )

pmid:23633679 24

Understanding their side effect profiles helps mitigate risks and structure safer, more effective cycles

Nature 547 (7661), 99103